Ultragenyx Pharmaceutical(US:RARE) Globenewswire·2026-03-18 17:35Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about the efficacy of its drug setrusumab for Osteogenesis Imperfecta [3][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Ultragenyx between August 3, 2023, and December 26, 2025, to discuss their legal rights [1][3]. - A federal securities class action has been filed against Ultragenyx, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives made false and misleading statements regarding the reliability of information on setrusumab's effects and downplayed the risks of the Phase III Orbit study failing to achieve significant results [5]. - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [6]. - On December 29, 2025, Ultragenyx announced that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, resulting in a further stock price decline of more than 42% [7][8].